Expert Perspective: Options for CAR-T Therapy in Thai Patients
🌈Expert Perspective: Options for CAR-T Therapy in Thai Patients🌈
🌺In the Hematology Department of Tongji Hospital in Shanghai, Director Li Ping provided a detailed overview of the condition and treatment journey of Ms. P, a middle-aged Thai patient with multiple myeloma. After undergoing multiple treatments and autologous hematopoietic stem cell transplants in Thailand, the patient experienced relapses, ultimately opting for CAR-T therapy in China. Director Li Ping explained that CAR-T therapy represents a significant breakthrough in the field of hematologic malignancies, offering remarkable efficacy for patients with multiple refractory recurrences. The fully humanized CAR-T therapy drug, FUCASO (Eque-cel), known for its low immunogenicity and long-term efficacy, has brought hope of cure to patients. Tongji Hospital’s rich experience and comprehensive management in CAR-T therapy ensure the safety and effectiveness of treatment, providing high-quality medical services to international patients.
🌼We will continue to follow up on the patient’s treatment progress and provide further updates.
#CARTTherapy #MultipleMyeloma #FUCASO #Equecel #TongjiHospital #Shanghai #MedicalInnovation #CancerTreatment #Hematology #PatientJourney #Immunotherapy #patientstory